Senator Jaziri Alkaf Abdillah Suffian (left) and Boo during Yong Tai’s virtual signing ceremony.
PETALING JAYA: Yong Tai Bhd has formalised its collaboration with China’s Shenzhen Kangtai Biological Products Co Ltd by entering into a definitive agreement for the Phase III clinical trials and commercialisation of the latter’s Covid-19 vaccine.
This cements the collaboration that was set up with the head of agreement framework signed in December 2020.
Yong Tai CEO Datuk Boo Kuang Loon said the agreement marks another milestone for the group in its foray into the pharmaceutical business and he is confident that the collaboration will bear fruit in the near term based on Shenzhen Kangtai’s track record.
Segments Covered
By Vaccine, Conjugate Vaccines are anticipated to account as the fastest-growing segment during the forecasted period. They are considered to be more robust over polysaccharide ones and hence are more preferred leading to high demand. It also covers a wide age group as it can vaccinate an infant from 6 weeks old to 5years of age and for people over 50 + age groups, reducing asymptomatic delivery of the bacteria, and thus resulting in marked group immunity.
By Product Type, Prevnar-13 is estimated to account for the fastest-growing segment during the forecasted period as it is recommended by the WHO as an efficient vaccine against pneumonia and has therefore been the widely adopted 13-valent PCV vaccines across the world. It has also been used as an essential vaccine for people above 50 age groups.
KUALA LUMPUR (Jan 12): Promising developments on the vaccine front have stirred investor interest in companies that venture into vaccine distribution, in hopes they will be in for bumper profits.
However, it is not clear at this juncture just how much or when these companies can cash in, given just the evaluation process alone for a vaccine to be approved for distribution and use in Malaysia will take five phases. The first phase alone which is the checking of the vaccine dossiers or research documents typically takes between 90 and 120 days, according to the Ministry of Health (MoH).
When contacted, property developer Yong Tai Bhd chief executive officer Datuk Wira Boo Kuang Loon said the company expects to bring its Chinese partner s vaccine into Malaysia by the third quarter of this year, at the earliest, on obtaining approval from the MoH s National Pharmaceutical Regulatory Agency (NPRA). Any vaccines or medicines to be imported into Malaysia for use here will require NPRA
Regulators in Asia are weighing approval for COVID-19 vaccines developed by Pfizer Inc with partner BioNTech SE, Moderna Inc and AstraZeneca Plc, but few nations expect to get significant supplies initially.
KUALA LUMPUR (Jan 6): Based on corporate announcements and news flow today, the following companies may be in focus tomorrow (Jan 7): Top Glove Corp Bhd, Hartalega Holdings Bhd, Techfast Holdings Bhd, LBS Bina Group Bhd, Censof Holdings Bhd, Supercomnet Technologies Bhd, Cymao Holdings Bhd, Sanichi Technology Bhd, AwanBiru Technology Bhd (Awantec) and Yong Tai Bhd.
BlackRock, which holds a 1.61% stake in
Top Glove Corp Bhd, voted against the election of six independent directors at the rubber glove maker s annual general meeting today, as it is of the view that the board had failed in its duty to mitigate the issues of migrant workers health and safety. The six independent directors are Datuk Lim Han Boon, Datuk Noripah Kamso, Datuk Norma Mansor, Tan Sri Rainer Althoff, Sharmila Sekarajasekaran and Lim Andy.